On Thursday, the U.S. Food and Drug Administration approved a new biosimilar designed to mimic Tysabri, one of Biogen's (Nasdaq: BIIB) MS products. Biosimilars, like generics, are typically more affordable versions of brand-name drugs.
On Thursday, the U.S. Food and Drug Administration approved a new biosimilar designed to mimic Tysabri, one of Biogen's (Nasdaq: BIIB) MS products. Biosimilars, like generics, are typically more affordable versions of brand-name drugs.
About Our Site:
The primary purpose of the site is to provide Real Estate & Mortgage information as it relates to today’s business environment. It can also be used to answer related question you might have about buying, selling, or financing real estate.